EGFR is a potential therapeutic target for highly glycosylated and aggressive pancreatic neuroendocrine neoplasms
暂无分享,去创建一个
A. Warshaw | J. Strosberg | R. Lu | Q. Ni | G. Luo | Shengming Deng | Zhiwen Xiao | Xianjun Yu | L. Ding | Huaxiang Xu | Xinzhe Zhu
[1] J. Cameron,et al. Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors , 2019, Annals of surgery.
[2] M. Dillhoff,et al. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients. , 2019, Annals of surgery.
[3] Kui Wu,et al. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system , 2019, Gut.
[4] S. Teichmann,et al. Comparative analysis of sequencing technologies for single-cell transcriptomics , 2019, Genome Biology.
[5] F. Vaisman,et al. CA19-9 as a Predictor of Worse Clinical Outcome in Medullary Thyroid Carcinoma , 2019, European Thyroid Journal.
[6] J. Mayerle,et al. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. , 2017, The lancet. Diabetes & endocrinology.
[7] Jie Chen,et al. Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors. , 2017, Oncology letters.
[8] Minhu Chen,et al. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms]. , 2017, Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery.
[9] R. Lu,et al. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer , 2017, Annals of surgery.
[10] P. Patel,et al. Glycosylation: a hallmark of cancer? , 2016, Glycoconjugate Journal.
[11] elliot k fishman,et al. Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Metz,et al. Consensus on biomarkers for neuroendocrine tumour disease. , 2015, The Lancet. Oncology.
[13] F. Basolo,et al. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer. , 2015, European journal of endocrinology.
[14] S. Pinho,et al. Glycosylation in cancer: mechanisms and clinical implications , 2015, Nature Reviews Cancer.
[15] J. Zyprych-Walczak,et al. The Impact of Normalization Methods on RNA-Seq Data Analysis , 2015, BioMed research international.
[16] Steven L Salzberg,et al. HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.
[17] G. Casazza,et al. Chromogranin A in Diagnosing and Monitoring Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Large Series from a Single Institution , 2014, Neuroendocrinology.
[18] T. Nagy,et al. Post-translational Glycoprotein Modifications Regulate Colon Cancer Stem Cells and Colon Adenoma Progression in Apcmin/+ Mice through Altered Wnt Receptor Signaling* , 2014, The Journal of Biological Chemistry.
[19] Zuqiang Liu,et al. CA125 is Superior to CA19-9 in Predicting the Resectability of Pancreatic Cancer , 2013, Journal of Gastrointestinal Surgery.
[20] R. Jensen,et al. Gastrointestinal hormones stimulate growth of Foregut Neuroendocrine Tumors by transactivating the EGF receptor. , 2013, Biochimica et biophysica acta.
[21] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.
[22] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[23] D. Hanahan,et al. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Jaw-Yuan Wang,et al. Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab , 2010, Annals of surgery.
[25] A. Scarpa,et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system , 2006, Virchows Archiv : an international journal of pathology.
[26] R. Lloyd,et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas , 2005, Modern Pathology.
[27] E. Seregni,et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors , 1999, Cancer.
[28] J. Claverie,et al. The significance of digital gene expression profiles. , 1997, Genome research.
[29] O. Ganda,et al. Alpha‐Fetoprotein Associated with Islet Cell Tumors , 1987, American journal of clinical oncology.
[30] Atit Silsirivanit. Glycosylation markers in cancer. , 2019, Advances in clinical chemistry.
[31] C. Gheorghe,et al. Metastatic neuroendocrine pancreatic tumor – Case report , 2018, Journal of medicine and life.
[32] Lili Xiao,et al. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy. , 2015, Asian Pacific journal of cancer prevention : APJCP.
[33] K. O'Byrne,et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. , 2012, The Lancet. Oncology.